PT - JOURNAL ARTICLE AU - Carole H. Sudre AU - Ayya Keshet AU - Mark S. Graham AU - Amit D. Joshi AU - Smadar Shilo AU - Hagai Rossman AU - Benjamin Murray AU - Erika Molteni AU - Kerstin Klaser AU - Liane D Canas AU - Michela Antonelli AU - Marc Modat AU - Joan Capdevila Pujol AU - Sajaysurya Ganesh AU - Jonathan Wolf AU - Tomer Meir AU - Andrew T. Chan AU - Claire J. Steves AU - Tim D. Spector AU - John S. Brownstein AU - Eran Segal AU - Sebastien Ourselin AU - Christina M. Astley TI - Anosmia and other SARS-CoV-2 positive test-associated symptoms, across three national, digital surveillance platforms as the COVID-19 pandemic and response unfolded: an observation study AID - 10.1101/2020.12.15.20248096 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.15.20248096 4099 - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20248096.short 4100 - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20248096.full AB - Background Multiple participatory surveillance platforms were developed across the world in response to the COVID-19 pandemic, providing a real-time understanding of community-wide COVID-19 epidemiology. During this time, testing criteria broadened and healthcare policies matured. We sought to test whether there were consistent associations of symptoms with SARS-CoV-2 test status across three national surveillance platforms, during periods of testing and policy changes, and whether inconsistencies could better inform our understanding and future studies as the COVID-19 pandemic progresses.Methods Four months (1st April 2020 to 31st July 2020) of observation through three volunteer COVID-19 digital surveillance platforms targeting communities in three countries (Israel, United Kingdom, and United States). Logistic regression of self-reported symptom on self-reported SARS-CoV-2 test status (or test access), adjusted for age and sex, in each of the study cohorts. Odds ratios over time were compared to known changes in testing policies and fluctuations in COVID-19 incidence.Findings Anosmia/ageusia was the strongest, most consistent symptom associated with a positive COVID-19 test, based on 658,325 tests (5% positive) from over 10 million respondents in three digital surveillance platforms using longitudinal and cross-sectional survey methodologies. During higher-incidence periods with broader testing criteria, core COVID-19 symptoms were more strongly associated with test status. Lower incidence periods had, overall, larger confidence intervals.Interpretation The strong association of anosmia/ageusia with self-reported SARS-CoV-2 test positivity is omnipresent, supporting its validity as a reliable COVID-19 signal, regardless of the participatory surveillance platform or testing policy. This analysis highlights that precise effect estimates, as well as an understanding of test access patterns to interpret differences, are best done only when incidence is high. These findings strongly support the need for testing access to be as open as possible both for real-time epidemiologic investigation and public health utility.Funding NIH, NIHR, Alzheimer’s Society, Wellcome TrustEvidence before this study As the COVID-19 pandemic has evolved, testing capacity expanded and governmental guidelines adapted, generally encouraging testing with a broader set of symptoms, not just fever with respiratory symptoms. In parallel, multiple large-scale citizen science digital surveillance platforms launched to complement knowledge from laboratory and somewhat smaller clinical studies. Symptoms such as loss of sense of smell have been identified as strongly predictive of COVID-19 infection in both clinical and syndromic surveillance analyses, and have therefore been used to inform these testing policy changes and access expansion.Added value of this study This study identifies symptoms that are or are not consistently associated with SARS-CoV-2 test positivity over time and across three country-based COVID-19 surveillance platforms in the United States, United Kingdom and Israel. These platforms are website and smartphone based, as well as cross-sectional and longitudinal. The study period of 4 months covers fluctuating COVID-19 prevalence during the fall of the first wave and, in some areas, rise of the second wave. In addition, the study period overlaps expansion of test access and test seeking. Importantly, these analyses track and highlight the value of individual symptoms to predict SARS-CoV-2 test positivity under a range of conditions.Implications of all the available evidence Despite differences in surveillance methodology, access to SARS-CoV-2 testing and disease prevalence, loss of sense of smell or taste was consistently the strongest predictor of COVID-19 infection across all platforms over time. As access to testing broadened, the relevance of COVID-like symptoms and consistency of their predictive ability became apparent. However, confidence bounds generally widened with a fall in COVID-19 incidence. Therefore, for the most robust symptom-based COVID-19 prediction models should consider surveillance data during periods of higher incidence and improved test access, and effect estimates that replicate across different epidemiologic conditions and platforms.Competing Interest StatementZoe Global Limited co-developed the app pro bono for non-commercial purposes. Investigators received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. JW, JCP, SG work for Zoe Global Limited and TDS and is consultant to Zoe Global Limited. ATC previously participated as investigator on a diet study unrelated to this work that was supported by Zoe Global Ltd. Funding StatementZoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare. Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research studies on data collected through the app are approved by King's College London Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all participants provided consent. This study was approved by the Boston Children's Hospital IRB (P00023700​). This study was approved by the Weizmann Institute of Science review board (IRB). The IRB waived informed consent as all identifying information was removed prior to analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIsrael Platform Tables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey. UK Platform Data used in this study is available to bona fide researchers through UK Health Data Research using the following link https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259 US Platform: Requests for access to the US Carnegie Mellon University/ Facebook COVID-19 Symptom Survey available via https://dataforgood.fb.com/docs/covid-19-symptom-survey-request-for-data-access/.